SCHEMBL51894

SCHEMBL51894

COC(=O)c1ccc(OC)c(N)c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.73
LMNA P02545 3/20 0.73
L3MBTL1 Q9Y468 3/20 0.73
HTT P42858 1/20 0.73
USP2 O75604 1/20 0.69
KDM4E B2RXH2 7/20 0.66
MAPT P10636 6/20 0.66
HPGD P15428 5/20 0.66
GAA P10253 2/20 0.66
HSD17B10 Q99714 2/20 0.66
GLA P06280 1/20 0.66
CASP1 P29466 1/20 0.66
CASP7 P55210 1/20 0.66
ATM Q13315 1/20 0.66
TUBB4A P04350 1/20 0.61
TUBB P07437 1/20 0.61
TUBA3C P0DPH7 1/20 0.61
TUBA1B P68363 1/20 0.61
TUBA4A P68366 1/20 0.61
TUBB4B P68371 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30427425 1.00 ALDH1A1 (0.73) ALDH1A1LMNAL3MBTL1HTTUSP2
Hydrochloric Acid SCHEMBL5065615 0.98 ALDH1A1 (0.71) ALDH1A1LMNAL3MBTL1HTTUSP2
SCHEMBL11146505 0.89 KMT2A (0.65) ALDH1A1LMNAL3MBTL1HTTUSP2
SCHEMBL155160 0.85 MAPT (0.62) ALDH1A1LMNAL3MBTL1HTTUSP2
SCHEMBL310457 0.85 ALDH1A1 (1.00) ALDH1A1LMNAL3MBTL1HTTUSP2
SCHEMBL27540714 0.84 USP2 (0.63) ALDH1A1LMNAL3MBTL1HTTUSP2
SCHEMBL7151804 0.83 MEN1 (0.73) ALDH1A1MAPTHPGDKMT2ANPC1
SCHEMBL30217617 0.83 ALDH1A1 (0.76) ALDH1A1LMNAL3MBTL1HTTUSP2
SCHEMBL761126 0.83 ALDH1A1 (0.76) ALDH1A1LMNAL3MBTL1HTTUSP2
SCHEMBL436586 0.83 HTT (0.76) ALDH1A1LMNAL3MBTL1HTTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 503 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12528777-B2 Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2026-01-20 US claimed
US-20250075147-A1 FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS OSMO LABS, PBC 2025-03-06 US claimed
CN-119039488-A Auxiliary agent with compatibility and nucleation performance, preparation method and application 合肥工业大学 2024-11-29 CN claimed
CN-113045504-B Dacoti preparation method of nylon 上海天慈国际药业有限公司 2024-09-17 CN claimed
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2023-11-09 US claimed
EP-4171569-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF Council of Scientific & Industrial Research (IN) 2023-05-03 EP claimed
WO-2022003712-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2022-01-06 WO claimed
CN-113045504-A Preparation method of dacomitinib 上海天慈国际药业有限公司 2021-06-29 CN claimed
US-20260144743-A1 COMPOUNDS TMEM16A LIMITED (GB) 2026-05-28 US disclosed
US-20260125400-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-05-07 US disclosed
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 US disclosed
EP-3856178-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-03-11 EP disclosed
EP-4699655-A2 COMPOUNDS TMEM16A LIMITED (GB) 2026-02-25 EP disclosed
US-20260022099-A1 ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF NEXYS THERAPEUTICS, INC. (US) 2026-01-22 US disclosed
WO-1992003408-A1 BENZANILIDE DERIVATIVES AND THEIR USE AS ANTI-ANTHEROSCLEROTIC AGENTS RHONE-POULENC RORER LIMITED (GB) 1992-03-05 WO disclosed
WO-1992003413-A1 DIPHENYLUREA DERIVATIVES RHONE-POULENC RORER LIMITED (GB) 1992-03-05 WO disclosed
WO-1992003412-A2 BENZAMIDE DERIVATIVES RHONE-POULENC RORER LIMITED (GB) 1992-03-05 WO disclosed
US-4392999-A COLORFAST BROWN, RED AND ORANGE CIBA-GEIGY CORPORATION (US) 1983-07-12 US disclosed
US-4229344-A Monazo pigments containing hydroxynaphthoylaminobenzimidazalone radical CIBA-GEIGY CORPORATION (US) 1980-10-21 US disclosed
US-4150046-A ORGANIC PIGMENTS HOECHST AKTIENGESELLSCHAFT (DE) 1979-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125400-A1 TYK2 DEGRADERS AND USES THEREOF TYK2, CSNK2A1, CSNK2A2 ALDH1A1 3930/4885LMNA 2666/4885L3MBTL1 2459/4885
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF ATG7, GOT1, LIPC ALDH1A1 295/4885LMNA 2696/4885L3MBTL1 1585/4885
US-20260144743-A1 COMPOUNDS CACNA1E, TMEM109, CACNA1C ALDH1A1 1592/4885LMNA 665/4885L3MBTL1 1483/4885
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH ALDH1A1 587/4885LMNA 1988/4885L3MBTL1 1163/4885
US-12528777-B2 Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof ATG7, GOT1, ULK1 ALDH1A1 601/4885LMNA 2223/4885L3MBTL1 930/4885
US-20260022099-A1 ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF AHR, NR1H4, CNR1 ALDH1A1 807/4885LMNA 3897/4885L3MBTL1 4220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.